Unlock the treasure on Mount Olympus with this little-known mining stock.
Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons
Download Free Report
Sven  Dethlefs net worth and biography

Sven Dethlefs Biography and Net Worth

Sven Dethlefs (Ph.D) became Executive Vice President, North America Commercial in August 2021, leading all commercial activities of Teva USA and Teva Canada’s Generic and Specialty businesses.

Headquartered in Parsippany, NJ, Teva USA’s generic medicines saved the US healthcare system $28.8B in 2020 alone, and in the US, 10 prescriptions are filled with a Teva product every second. Teva USA maintains leadership positions with broad generic and specialty portfolios across varying therapeutic conditions, including movement disorders, mental health and respiratory. Teva Canada, headquartered in Toronto, has provided affordable healthcare solutions to Canadians for over 50 years, with currently more than 179,000 prescriptions filled each day.

Sven Dethlefs has been part of Teva’s Executive Management team since 2017, where he served as Executive Vice President, Global Marketing and Portfolio, assuming responsibility for International Markets, Commercial in 2021. He also held leadership roles in Teva’s Global Specialty business, Commercial European business and Global Operations (TGO). Sven has played an integral role in optimizing Teva's vast global portfolio, in developing the R&D pipeline strategy, and leading global marketing teams.

Sven joined Teva as General Manager, Teva Germany in 2008. Prior to joining Teva, he served for over eleven years as a partner at McKinsey & Company.

Sven received his Ph.D. in biochemistry from the FU Berlin/Pasteur Institute Paris.

What is Sven Dethlefs' net worth?

The estimated net worth of Sven Dethlefs is at least $2.25 million as of March 6th, 2023. Dr. Dethlefs owns 223,447 shares of Teva Pharmaceutical Industries stock worth more than $2,252,346 as of September 28th. This net worth approximation does not reflect any other assets that Dr. Dethlefs may own. Additionally, Dr. Dethlefs receives a salary of $1,760,000.00 as EVP at Teva Pharmaceutical Industries. Learn More about Sven Dethlefs' net worth.

How old is Sven Dethlefs?

Dr. Dethlefs is currently 54 years old. There are 6 older executives and no younger executives at Teva Pharmaceutical Industries. The oldest executive at Teva Pharmaceutical Industries is Mr. Eric Drape, Exec. VP of Global Operations, who is 61 years old. Learn More on Sven Dethlefs' age.

What is Sven Dethlefs' salary?

As the EVP of Teva Pharmaceutical Industries Limited, Dr. Dethlefs earns $1,760,000.00 per year. There are 3 executives that earn more than Dr. Dethlefs. The highest earning executive at Teva Pharmaceutical Industries is Mr. Eliyahu Sharon Kalif, Exec. VP & CFO, who commands a salary of $2,010,000.00 per year. Learn More on Sven Dethlefs' salary.

How do I contact Sven Dethlefs?

The corporate mailing address for Dr. Dethlefs and other Teva Pharmaceutical Industries executives is 5 BAZEL ST P O B 3190, PETACH TIKVA L3, 49131. Teva Pharmaceutical Industries can also be reached via phone at (723) 914-8213 and via email at [email protected]. Learn More on Sven Dethlefs' contact information.

Has Sven Dethlefs been buying or selling shares of Teva Pharmaceutical Industries?

Sven Dethlefs has not been actively trading shares of Teva Pharmaceutical Industries during the last quarter. Most recently, Sven Dethlefs sold 19,355 shares of the business's stock in a transaction on Monday, March 6th. The shares were sold at an average price of $9.93, for a transaction totalling $192,195.15. Following the completion of the sale, the executive vice president now directly owns 223,447 shares of the company's stock, valued at $2,218,828.71. Learn More on Sven Dethlefs' trading history.

Who are Teva Pharmaceutical Industries' active insiders?

Teva Pharmaceutical Industries' insider roster includes Rosemary Crane (Director), Richard Daniell (VP), Sven Dethlefs (EVP), Eric Drape (VP), Hafrun Fridriksdottir (VP), Eric Hughes (insider), Eliyahu Kalif (CFO), Mark Sabag (Insider), Eli Shani (EVP), David Stark (VP), and Amir Weiss (CAO). Learn More on Teva Pharmaceutical Industries' active insiders.

Are insiders buying or selling shares of Teva Pharmaceutical Industries?

During the last twelve months, insiders at the sold shares 7 times. They sold a total of 248,732 shares worth more than $2,371,972.97. The most recent insider tranaction occured on August, 7th when CFO Eliyahu Sharon Kalif sold 35,125 shares worth more than $341,766.25. Insiders at Teva Pharmaceutical Industries own 0.6% of the company. Learn More about insider trades at Teva Pharmaceutical Industries.

Information on this page was last updated on 8/7/2023.

Sven Dethlefs Insider Trading History at Teva Pharmaceutical Industries

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/6/2023Sell19,355$9.93$192,195.15223,447View SEC Filing Icon  
2/28/2023Sell59,655$9.89$589,987.95165,381View SEC Filing Icon  
2/9/2022Sell4,138$9.06$37,490.28View SEC Filing Icon  
3/18/2019Sell632$16.63$10,510.169,781View SEC Filing Icon  
3/12/2019Sell647$15.67$10,138.499,249View SEC Filing Icon  
3/4/2019Sell606$16.88$10,229.288,664View SEC Filing Icon  
9/18/2018Sell625$23.71$14,818.757,890View SEC Filing Icon  
8/3/2018Buy2,000$21.92$43,840.006,445View SEC Filing Icon  
3/19/2018Sell571$17.88$10,209.485,016View SEC Filing Icon  
See Full Table

Sven Dethlefs Buying and Selling Activity at Teva Pharmaceutical Industries

This chart shows Sven Dethlefs's buying and selling at Teva Pharmaceutical Industries by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Teva Pharmaceutical Industries Company Overview

Teva Pharmaceutical Industries logo
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also manufactures and sells active pharmaceutical ingredients, as well as provides contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. In addition, it focuses on the central nervous system (CNS), pain, respiratory, and oncology areas. The company's products portfolio in the CNS field comprises Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; and AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; respiratory therapeutic area includes ProAir RespiClick, QVAR, ProAir Digihaler, AirDuo Digihaler, ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease; and oncology therapeutic field consists of Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.
Read More

Today's Range

Now: $10.22
Low: $10.01
High: $10.25

50 Day Range

MA: $9.60
Low: $8.29
High: $10.70

2 Week Range

Now: $10.22
Low: $7.09
High: $11.44


5,836,341 shs

Average Volume

10,690,792 shs

Market Capitalization

$11.45 billion

P/E Ratio


Dividend Yield



Unlock the treasure on Mount Olympus with this little-known mining stock.
Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons
Download Free Report